Titan Spine closes financing round; positioned to expand US sales of interbody fusion devices with nanoLOCK: 5 things to know

Written by Megan Wood | July 13, 2016 | Print  |

Mequon, Wis.-based Titan Spine closed a financing round with Southlake (Texas) Equity Group.

Here are five things to know:

 

1. The company plans to use the funding to widen the U.S. footprint of its Endoskeleton line of titanium interbody fusion implants.

 

2. Titan Spine will also use the proceeds to help introduce its next-generation nanoLOCK surface technology.

 

3. CMS recently approved a new code for interbody fusion device nanotextured surfaces. Titan Spine's nanoLOCK technology is the only approved product to use the code.

 

4. Southlake Equity Group partnered with Titan Spine as it felt the company offered a "line of spinal devices substantially differentiated from other implants on the market."

 

5. Titan Spine is a surface technology company developing spinal interbody fusion devices.

 

"We have historically grown organically, but feel the time is right to aggressively capitalize the company to take advantage of the accelerating shift within the marketplace toward surface-enhanced titanium interbody fusion devices," said Peter Ullrich, MD, CEO, Titan Spine.

 

More articles on devices:
Stryker VP sells 10k company shares: 5 points
92% of ConforMIS iTotal CR patients report satisfaction, improved KOOS: 3 things to know
Corin Orthopaedics offers $33M to buy Wright Medical's large joints business: 7 key notes

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months